BrightPath Biotherapeutics, The Current Fiscal Year Net Income Loss Widened in Downward Revision

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Mon Mar 24, 2025 6:00 pm JST Revision

4594 BrightPath Biotherapeutics Co., Ltd. 【J-GAAP】

Guidance Update Report

BrightPath Biotherapeutics Co., Ltd. <4594> [TSE Growth] announced a performance revision after the market closed on March 24th (18:00). The net income/loss (non-consolidated) for the fiscal year ending March 2025 has been revised downward from an expected loss of 0.92 billion yen to a loss of 1.1 billion yen (compared to a loss of 1.16 billion yen in the previous period), indicating an expansion in the loss margin.

Based on the downwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (2H) net income/loss has been revised downward from an expected loss of 0.38 billion yen to a loss of 0.57 billion yen (compared to a loss of 0.61 billion yen in the same period of the previous year), indicating an expansion in the loss margin.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	0	-383	-388	-389	-4.4	0	Nov 8, 2024	J-GAAP
Oct - Mar, 2024 New	1	-572	-569	-571	-6.4	0	Mar 24, 2025	J-GAAP
Revision Rate	－	-49.3%	-46.6%	-46.8%	-46.9%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	0	-925	-925	-927	-10.4	0	May 10, 2024	J-GAAP
Mar, 2025 New	1	-1,114	-1,106	-1,109	-12.4	0	Mar 24, 2025	J-GAAP
Revision Rate	－	-20.4%	-19.6%	-19.6%	-19.7%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	0	-605	-607	-615	-9.6	0	May 10, 2024	J-GAAP
Oct - Mar, 2024 Guidance	1	-572	-569	-571	-6.4	0	Mar 24, 2025	J-GAAP
YoY	－	+5.5%	+6.3%	+7.2%	+33.4%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	5	-1,467	-1,473	-1,485	-24.9	0	May 12, 2023	J-GAAP
Mar, 2024	0	-1,155	-1,158	-1,168	-18.2	0	May 10, 2024	J-GAAP
Mar, 2025 Guidance	1	-1,114	-1,106	-1,109	-12.4	0	Mar 24, 2025	J-GAAP
YoY	－	+3.5%	+4.5%	+5.1%	+31.9%